应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AUPH Aurinia Pharmaceuticals Inc
交易中 07-22 11:51:37 EDT
5.44
-0.12
-2.12%
最高
5.65
最低
5.41
成交量
43.62万
今开
5.58
昨收
5.56
日振幅
4.32%
总市值
7.76亿
流通市值
6.92亿
总股本
1.43亿
成交额
239.14万
换手率
0.34%
流通股本
1.27亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
暂无数据
公司概况
公司名称:
Aurinia Pharmaceuticals Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的(加拿大阿尔伯塔省)。Aurinia制药是一家完全整合的生物制药公司,专注于提供治疗目标患者群体的疗法,这些患者群体受到自身免疫、肾脏和罕见病的影响,医疗需求未得到满足。2021年1月,Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS(voclosporin),用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂,当与霉酚酸酯(MMF)(尽管MMF目前尚未被批准)和类固醇联合使用时,已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶,LUPKYNIS降低细胞因子活化,阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞,从而防止蛋白尿。
发行价格:
--
{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals Inc","latestPrice":5.442,"timestamp":1721663489432,"preClose":5.56,"halted":0,"volume":436200,"delay":0,"floatShares":127091573,"shares":142663526,"eps":-0.435739,"marketStatus":"交易中","marketStatusCode":2,"change":-0.118,"latestTime":"07-22 11:51:37 EDT","open":5.58,"high":5.65,"low":5.41,"amount":2391423.0544800004,"amplitude":0.043165,"askPrice":5.45,"askSize":1400,"bidPrice":5.44,"bidSize":1269,"shortable":3,"etf":0,"ttmEps":-0.435739,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"listingDate":951454800000,"adjPreClose":5.56,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":5.58,"preClose":5.56,"latestTime":"09:29 EDT","volume":420,"amount":2342.8003200000003,"timestamp":1721654970025},"postHourTrading":{"tag":"盘后","latestPrice":5.63,"preClose":5.56,"latestTime":"19:40 EDT","volume":15691,"amount":87238.0817,"timestamp":1721432431372},"volumeRatio":0.755374,"impliedVol":0.4883,"impliedVolPercentile":0.0637},"requestUrl":"/m/hq/s/AUPH","defaultTab":"news","newsList":[],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":0.0258},{"period":"3month","weight":0.1142},{"period":"6month","weight":-0.305},{"period":"1year","weight":-0.504},{"period":"ytd","weight":-0.3815}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的(加拿大阿尔伯塔省)。Aurinia制药是一家完全整合的生物制药公司,专注于提供治疗目标患者群体的疗法,这些患者群体受到自身免疫、肾脏和罕见病的影响,医疗需求未得到满足。2021年1月,Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS(voclosporin),用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂,当与霉酚酸酯(MMF)(尽管MMF目前尚未被批准)和类固醇联合使用时,已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶,LUPKYNIS降低细胞因子活化,阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞,从而防止蛋白尿。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.106403},{"month":2,"riseRate":0.5,"avgChangeRate":0.009372},{"month":3,"riseRate":0.4,"avgChangeRate":0.102117},{"month":4,"riseRate":0.6,"avgChangeRate":-0.012088},{"month":5,"riseRate":0.6,"avgChangeRate":-0.004093},{"month":6,"riseRate":0.4,"avgChangeRate":-0.030211},{"month":7,"riseRate":0.5,"avgChangeRate":0.030952},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.068337},{"month":9,"riseRate":0.444444,"avgChangeRate":0.078247},{"month":10,"riseRate":0.6,"avgChangeRate":0.041208},{"month":11,"riseRate":0.5,"avgChangeRate":-0.001599},{"month":12,"riseRate":0.4,"avgChangeRate":0.111111}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals Inc","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aurinia Pharmaceuticals Inc,AUPH,Aurinia Pharmaceuticals Inc股票,Aurinia Pharmaceuticals Inc股票老虎,Aurinia Pharmaceuticals Inc股票老虎国际,Aurinia Pharmaceuticals Inc行情,Aurinia Pharmaceuticals Inc股票行情,Aurinia Pharmaceuticals Inc股价,Aurinia Pharmaceuticals Inc股市,Aurinia Pharmaceuticals Inc股票价格,Aurinia Pharmaceuticals Inc股票交易,Aurinia Pharmaceuticals Inc股票购买,Aurinia Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}